Markers of Treatment Response toMethotrexate in Rheumatoid Arthritis: Where Do We Stand?

被引：45
作者：
Halilova, Karina I. [1 ]
Brown, Elizabeth E. [2 ]
Morgan, Sarah L. [1 ]
Bridges, S. Louis, Jr. [1 ]
Hwang, Min-Ho [1 ]
Arnett, Donna K. [2 ]
Danila, Maria I. [1 ]
机构：
[1] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA
来源：
INTERNATIONAL JOURNAL OF RHEUMATOLOGY | 2012年 / 2012卷
关键词：
D O I：
10.1155/2012/978396
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). However, despite its efficacy and affordability, additional DMARDs or biologic agents are often required in order to achieve the recommended goals of low disease activity or remission. Although well tolerated by most, some patients develop important side effects such as cytopenias, gastrointestinal adverse events (stomatitis, nausea), or abnormal liver function tests, which may limit its use and may result in additional health care costs. Given the clinical implications of widespread use of MTX in RA, various studies have evaluated the role of potential biomarkers in predicting treatment effectiveness of MTX. These biomarkers include RBC MTX polyglutamate (PG) levels; genetic variation in genes from relevant biological and metabolic pathways; gene expression profiles; serum proteins. This paper provides an update on the current data regarding biomarkers of treatment response to MTX.
引用
收藏
页数：7
相关论文
共 67 条
  • [1] Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis
    Aggarwal, A
    Misra, R
    [J]. RHEUMATOLOGY INTERNATIONAL, 2003, 23 (03) : 134 - 137
  • [2] INHIBITION OF 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBOTIDE TRANSFORMYLASE, ADENOSINE-DEAMINASE AND 5'-ADENYLATE DEAMINASE BY POLYGLUTAMATES OF METHOTREXATE AND OXIDIZED FOLATES AND BY 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBOSIDE AND RIBOTIDE
    BAGGOTT, JE
    VAUGHN, WH
    HUDSON, BB
    [J]. BIOCHEMICAL JOURNAL, 1986, 236 (01) : 193 - 200
  • [3] Analysis of Intracellular Methotrexate Polyglutamates in Patients With Juvenile Idiopathic Arthritis Effect of Route of Administration on Variability in Intracellular Methotrexate Polyglutamate Concentrations
    Becker, Mara L.
    van Haandel, Leon
    Gaedigk, Roger
    Lasky, Andrew
    Hoeltzel, Mark
    Stobaugh, John
    Leeder, J. Steven
    [J]. ARTHRITIS AND RHEUMATISM, 2010, 62 (06): : 1803 - 1812
  • [4] Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature
    Benucci, Maurizio
    Saviola, Gianantonio
    Manfredi, Mariangela
    Sarzi-Puttini, Piercarlo
    Atzeni, Fabiola
    [J]. INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2011, 2011
  • [5] Bridges Jr S. L., 2012, TREATMENT EFFICACY T
  • [6] Bridges SL, 2007, BULL HOSP JT DIS, V65, P174
  • [7] Genetic Risk Score Predicting Risk of Rheumatoid Arthritis Phenotypes and Age of Symptom Onset
    Chibnik, Lori B.
    Keenan, Brendan T.
    Cui, Jing
    Liao, Katherine P.
    Costenbader, Karen H.
    Plenge, Robert M.
    Karlson, Elizabeth W.
    [J]. PLOS ONE, 2011, 6 (09):
  • [8] Constantin A, 1998, ARTHRITIS RHEUM, V41, P48, DOI 10.1002/1529-0131(199801)41:1<48::AID-ART7>3.0.CO
  • [9] 2-K
  • [10] The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept
    Criswell, LA
    Lum, RF
    Turner, KN
    Woehl, B
    Zhu, YQ
    Wang, JY
    Tiwari, HK
    Edberg, JC
    Kimberly, RP
    Moreland, LW
    Seldin, MF
    Bridges, SL
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : 2750 - 2756
1234567